Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415007 · ClinicalTrials.gov registry record · NA
GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer
A NA study of Cancer, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05415007: Recruiting NA study of Cancer, sponsored by Stanford University.
NCT05415007 is a NA study of Cancer that is actively recruiting participants, run by Stanford University. The registered enrollment target is 40 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05415007, a NA study of Cancer, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.
Primary Outcome
Measurement will be based on the percentage of caregivers who provide consent, and are retained in the program through 1-month follow-up.
Conditions Studied
Interventions
- BEHAVIORAL Treatment as usual (TAU)
- BEHAVIORAL GOLD Program
Study Locations (1)
California
- Stanford Cancer Institute - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05415007 shows while recruiting
NCT05415007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Treatment as usual (TAU) is the first listed.
NCT05415007 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05415007 about?
NCT05415007 is a clinical study titled "GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer". The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.
What is the current status of trial NCT05415007?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2022-09-21. Estimated completion is 2027-06-30.
What conditions does trial NCT05415007 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT05415007?
The interventions under investigation include: Treatment as usual (TAU) (BEHAVIORAL), GOLD Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT05415007?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05415007 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05415007's enrollment target sits among peer trials
40 461st of 615 higher than 146 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI